Dealing with state regulation of the pharma supply chain

A seminar shares key observations and learnings from the first round of direct price negotiations.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

Respective industry and government agendas could significantly reshape the US prescription drug market.

Ensuring that essential treatments reach patients safely and efficiently is an increasing imperative in today's pharma landscape.